Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2019  |  Volume : 15  |  Issue : 4  |  Page : 743--750

Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions


Qin Qin1, Baosheng Li2 
1 Department of Oncology, The Second Clinical Medical College, Jingzhou Central Hospital, Yangtze University, Jingzhou, Hubei 434020, China
2 Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250117, China

Correspondence Address:
Baosheng Li
Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250117
China

The development of inhibitors of immune checkpoints has revolutionized the treatment for a subset of patients with advanced nonsmall cell lung cancer (NSCLC), resulting in promising clinical outcomes and durable responses. Pembrolizumab, a humanized anti-programmed cell death-1 (PD-1) antibody, has been approved as a first-line treatment for patients with advanced NSCLC with PD-L1 expression of ≥50% and as a second-line treatment for PD-L1 expression of ≥1%. Pembrolizumab in combination with standard chemotherapy has shown better clinical outcomes than chemotherapy as a first-line therapy in patients with advanced NSCLC without targetable mutations, regardless of PD-L1 expression. In this review, we summarized the current indications of pembrolizumab for NSCLC, briefly described immune-relevant pneumonitis and discussed potential biomarkers to predict clinical efficacy.


How to cite this article:
Qin Q, Li B. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.J Can Res Ther 2019;15:743-750


How to cite this URL:
Qin Q, Li B. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions. J Can Res Ther [serial online] 2019 [cited 2019 Sep 22 ];15:743-750
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2019;volume=15;issue=4;spage=743;epage=750;aulast=Qin;type=0